Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.

  title={Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.},
  author={David V. Erbe and Suyue Wang and Yan-Ling Zhang and Kimberly B. Harding and Leslie Kung and May S Tam and Leslie Stolz and Yuzhe Xing and Sarah Furey and Ariful Qadri and Lori D. Klaman and James Finbarr Tobin},
  journal={Molecular pharmacology},
  volume={67 1},
Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test. In addition, treatment of rodents improved lipid profiles, with significantly lowered triglyceride and free fatty acid levels. These results suggested that this therapeutic activity might involve… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 11 extracted citations

Past and current perspective on new therapeutic targets for Type-II diabetes

Drug design, development and therapy • 2017
View 11 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 42 references

Mechanistic toxicogenomic analysis of WAY-144122 administration in Sprague-Dawley rats.

Toxicology and applied pharmacology • 2004
View 4 Excerpts
Highly Influenced

The PPARs: from orphan receptors to drug discovery.

Journal of medicinal chemistry • 2000
View 4 Excerpts
Highly Influenced

Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate.

The Journal of biological chemistry • 1997
View 2 Excerpts
Highly Influenced

Thiazolidinedione use, fluid retention and congested heart failure

RW Nesto, D Bell, +7 authors S Smith
Circulation • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…